DIVISION OF HEMATOLOGY ONCOLOGY

Sponsor/Grant Type

Project Title

Start Date

End Date

Emanuel Peter

NIH/Nat. Center for Research Resources (Co-I)

Arkansas Center for Clinical & Translational Research

7/14/09

3/31/2014

Health Resources and ServicesAdministration  (HRSA) (PI)

Health Care and Other Facilities Awards Special Congressional Initiative

8/1/2009

7/31/2012

Health Resources and Services Administration (HRSA) (PI)

Center (Health Care and Other Facilities) University of Arkansas for Medical Sciences - The Thyroid Diagnostic

9/1/2008

8/31/2010

Pathogenic Alteration in Gene Specific RNA Translational Regulation in MPDS

NIH/NCI (PI)

North American Juvenile Myelomonocytic Leukemia Project

4/10/2009

Open enrollment

Govindarajan, Rangaswamy

Bayer (PI)

109260, Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON)

5/20/2009

Open enrollment

ARIAD (PI)

104726, A Pivotal Trial to Determine the Efficacy and Safety of AP23573 when Administered as Maintenance Therapy to Patients with Metastatic Soft-tissue or Bone Sarcomas

11/4/2008

Open enrollment

Sanofi Aventis (PI)

2007-12, A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Aflibercept versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer

6/5/2008

Open enrollment

Genentech, Inc. (PI)

2005-13-VA, Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma

5/8/2008

Open enrollment

CTSU (PI)

E5103, A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

8/4/2009

Open enrollment

CTSU (PI)

CTSU CALGB 30607 Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinumb-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer

4/21/2009

Open enrollment

CTSU (PI)

CTSU E1305 A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in patients with Recurrent or Metastatic Head and Neck Cancer

4/13/2009

Open enrollment

CTSU (PI)

CTSU N0147-VA, A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer

11/17/2008

Open enrollment

CTSU (PI)

CTSU N0147, A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer

12/9/2004

Open enrollment

CTSU (PI)

CTSU 90202, A Randomized double-blind, placebo-controlled phase III study of early versus standard Zoledronic acid to prevent skeletal related events in men with prostate cancer metastatic to bone

10/14/2004

Open enrollment

CTSU (PI)

CTSU E2805 ASSURE: Adjuvant Sorafenib or Sunitinib for unfavorable renal carcinoma

9/25/2006

Open enrollment

CTSU (PI)

CTSU E3805 CHAARTED: ChemoHormonal Therapy versus Androgen Ablation randomized trial for extensive disease in prostate cancer

11/02/2006

Open enrollment

CTSU (PI)

CTSU PACCT-1 Program for the assessment of clinical cancer tests (PACCT-1): Trial assigning IndividuaLized options for treatment: The TAILORx Trial

9/25/2006

Open enrollment

Local not funded (PI)

0037_2008I Impact of Thiazolidinediones (TZD) on survival among male diabetic veterans diagnosed with Squamous Cell Carcinoma of Head and Neck (SCCHN)

2/8/2008

Open enrollment

Herman, Damir

Fashion Footwear Association of New York (PI)

Deep Sequencing of the Breast Cancer Transcriptome

7/1/2009

6/30/2010

Hutchins, Laura

NIH/Nat. Center for Research Resources (Sub-I)

Arkansas Center for Clinical & Translational Research

7/14/09

3/31/2014

NIH/Nat. Cancer Institute (PI)

caBIG CTMS Workspace Planning and Monitoring Task Force

2/15/2009

2/14/2010

Department of the Army (Co-I)

Vaccination of high-risk breast cancer patients with carbohydrate mimicking peptides

4/24/2006

5/24/2011

Winthrop Rockefeller Foundation (PI)

Leukemia and Lymphoma Program

8/1/2007

7/31/2012

Arkansas Breast Cancer Research Program

Support the Development of the caBIG Cancer Translational Research Core

7/1/2007

6/30/2010

UAMS Foundation Medical Research Endowment (PI)

81687, Determination of the degree of tumor vessel heterogeneity as a potential predictive factor for chemotherapy

1/1/2008

Open enrollment

Adnexus, BMS (PI)

107880 Phase 1, Open Label, Multi-Center Study to Evaluate the Safety and Tolerability of CT-322 Administered in Combination with Focal Brain Radiotherapy and Temozolomide to Subjects with Newly Diagnosed Glioblastoma Multiforme

4/8/2009

Open enrollment

Pfizer (PI)

106646 A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols

8/28/2008

Open enrollment

Vical (PI)

UARK 2006-44 A Phase 3 Clinical trial to evaluate the safety and efficacy of treatment with 2 mg dose Intralesional Allovectin-7® compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in subjects with recurrent metastatic melanoma, Vical Protocol LX01-315

2/8/2007

Open enrollment

SWOG (PI)

SWOG 0518 Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients

1/20/2009

Open enrollment

SWOG (PI)

SWOG 9007 Cytogenetic studies in leukemia patients

8/20/1991

Open enrollment

SWOG (PI)

SWOG 9910 Leukemia centralized reference laboratories and tissue repositories - consent to perform cellular and molecular studies in leukemia patients

9/23/1999

Open enrollment

SWOG (PI)

SWOG 9925 Lung cancer specimen repository protocol, ancillary

7/25/2001

Open enrollment

SWOG (PI)

SWOG E5597 A Phase III chemoprevention trial of selenium supplementation in persons with resected stage I non-small cell lung cancer

2/12/2002

Open enrollment

CTSU (PI)

CTSU E1697 Phase III randomized study of four weeks of high dose IFN-alpha2b in stage T3 - T4 or N1 (microscopic) melanoma

2/19/2004

Open enrollment

SWOG (PI)

SWOG 0221 Phase III trial of continuous schedule AC + G vs. every 2 week schedule AC, followed by Paclitaxel given either every 2 weeks or weekly for 12 weeks as post-operative adjuvant therapy in node-positive or high-risk node-negative breast cancer

5/25/2004

Open enrollment

SWOG (PI)

SWOG 0106 Post-consolidation therapy with Gemtuzumab Ozogamicin (Mylotarg) or no-additional therapy for patients under age 61 with previously untreated DeNovo acute myeloid leukemia (AML)

12/17/2004

Open enrollment

SWOG (PI)

SWOG 0307 Phase II trial of bisphosphonates as adjuvant therapy for primary breast cancer

6/5/2006

Open enrollment

SWOG (PI)

SWOG 0605 A Phase II study of Lenalidomide (Revlimid) (NSC-703813) for previously untreated non-M3, deletion 5q acute myeloid leukemia (AML) in patients 60 or older who are not candidates of remission induction chemotherapy

11/16/2006

Open enrollment

SWOG (PI)

SWOG 0533 A pilot trial of Cisplatin/Etoposide/Radiotherapy followed by consolidation Docetaxel and the addition of Bevacizumab (NSC-704865) in three cohorts of patients with inoperable locally advanced stage III non-small cell lung cancer only cohort 1 (BOTH LOW AND HIGH RISK STRATA)

1/5/2007

Open enrollment

SWOG (PI)

SWOG 0500 A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell levels at first follow-up assessment

6/19/2007

Open enrollment

SWOG (PI)

SWOG 0350 Phase II trial of Cisplatin plus Etoposide plus Gemcitabine plus Solumedrol (PEGS) in Peripheral T-Cell non-Hodgkin’s lymphoma

1/11/2006

Open enrollment

Local not funded (PI)

109857, Alterations in the Bcl-2 Family Proteins in the Peripheral Blood Following Treatment with Taxanes in Patients with Breast Cancer

6/9/2009

Open enrollment

Local not funded (PI)

107455 A pilot study to quantify the variance between number of circulating tumor cells (CTCs) from the veins draining the tumor, the peripheral venous system, and the arterial system in individuals with Stage II-III colon cancer who will be undergoing definitive surgical resection

1/20/2009

Open enrollment

Liu, Lucy

NIH/NCI (Co-I)

North American Juvenile Myelomonocytic Leukemia Project

4/10/2009

Open enrollment

Maddox, Anne-Marie

Sapphire Therapeutics (PI)

99509, A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Anamorelin HCl Dose Range Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients with NSCLC

11/12/2008

Open enrollment

Genzyme (PI)

2006-20, A Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabin versus Cytarabine Alone in Adult Patients > 55 Years Old with Acute Myelogenous Leukemia (AML) who have Relapsed or are Refractory after Receiving up to Two Prior Induction Regimens

9/19/2006

Open enrollment

OSI Pharmaceuticals (PI)

UARK 2006-42, Protocol number OSI-774-302: A multi-center, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection and with or without adjuvant chemotherapy in patients with stage IB-IIIA non small cell lung carcinoma who have EGFR-positive tumors

2/16/2007

Open enrollment

Local not funded (PI)

107460, An Open Label Treatment Protocol for the Use of Voraxaze as Adjunctive Treatment for Patients Experiencing or at Risk of Methotrexate Toxicity

2/4/2009

Open enrollment

Makhoul, Issam

Fashion Footwear Association of New York (PI)

Unraveling the Mystery of Triple Negative Breast Cancer

7/1//2009

6/30/2010

OSI Pharmaceuticals(PI)

UARK 2004-19 Randomized, double-blind multi-center phase II study of time to progression on Fulvestrant in combination with Erlotinib or placebo in hormone receptor-positive metastatic breast cancer (MBC) subjects who progressed on first line hormonal therapy

09/22/2006

Open enrollment

Local not funded (PI)

UARK 2006-53, Cetuximab-Related First Infusion Reaction Rate in Cancer Patients

1/3/2007

Open enrollment

Mehta, Paulette

NIH/National Center on Minority Health and Health Disparities (Co-I)

Colorectal Cancer Education and Screening Program (CCESP)

7/1/2008

3/31/2013